Treating cells with the estrogen receptor antagonist ICI182,780 (100 nM; for two hours before treatment with estradiol) did not alter the blocking effect of Fuling, indicating that Fuling inhibits motility of endometrial cancer cells independently of estrogen receptor antagonist. The gene discussed is ESR1; the disease is endometrial cancer.